 Ascendis Pharma AS NASDAQ: ASND has announced preliminary 58-week results from the continuing open-label extension OLE portion of the Phase 2 PaTH Forward Trial evaluating TransCon PTH in adult subjects with hypoparathyroidism HP. Key Findings of the Preliminary OLE Results: Fifty-eight subjects continue in the open-label extension beyond 58 weeks as of May 7. 